Loading
Life sciences · Journal article
Future Pharmacology · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cancer remains a significant global health challenge, underscoring the need for active therapeutic strategies that target the key molecular determinants of tumor progression. Naringenin, a flavonoid prevalent in the diet and abundant in citrus fruits, has emerged as a promising anticancer agent due to its ability to regulate multiple oncogenic signaling pathways involved in cancer initiation, progression, and therapeutic resistance. This review highlights the molecular mechanisms through which naringenin modulates essential signaling networks, such as the PI3K/Akt/mTOR, NF-κB, MAPK, and TGF-β pathways, thereby suppressing cancer cell proliferation, inducing apoptosis, inhibiting angiogenesis, and preventing metastatic spread. Compared with previous reviews that mainly summarized the general pharmacological properties of naringenin, this review provides an integrated and critical analysis of cancer-related signaling networks, chemoresistance, therapeutic combinations, and emerging translational strategies. Importantly, it highlights the persistent gap between promising pre-clinical results and limited clinical evidence, and it emphasizes the pharmacokinetic, bioavailability, and safety challenges that need to be addressed for clinical translation. Finally, we highlight the existing challenges, knowledge gaps, and future perspectives for clinical translation to encourage the development of naringenin-based cancer therapeutics.